Brian M. Gallagher

Biography

 Dr. Gallagher, Jr. is a Partner at SR One Ltd. He established the SR One Boston office in 2010 and is focused on building innovative therapeutic and life science companies. He currently represents SR One on the boards of Aileron Therapeutics, Constellation Pharmaceuticals, Nimbus Discovery, RaNA Therapeutics, and River Vision, and co-manages portfolio companies Spero Therapeutics and Calcimedica. He previously led the firm's investments in Dicerna Pharmaceuticals (NASDAQ: DRNA) and SpringLeaf Therapeutics. He has over 15 years of investing, business development, operational, and R&D experience in both biotechnology and large pharma companies. He joined SR One from Sirtris Pharmaceuticals where he was responsible for corporate development, operations, and post-merger integration following the $720M acquisition of Sirtris by GlaxoSmithKline in 2008. Prior to Sirtris, Brian worked with Alantos Pharmaceuticals. There, he played key roles in the R&D and business development activities, and led many aspects of the post-merger integration following the $300M acquisition of Alantos by Amgen in 2007. Brian began his career in R&D at the Japanese pharma Eisai, where he was a group leader for multiple programs in the oncology and inflammation/immunology therapeutic areas. He is an inventor on over twenty-five patents and patent applications, and is the senior author of a number of scientific publications. He currently serves on the Industry Advisory Boards for NYU Medical School and the National Brain Tumor Society, the editorial board of the journal Marine Drugs, as a mentor for MassBio MassCONNECT, and is a peer reviewer for numerous journals and research funding authorities. Brian received his MS and PhD in organic chemistry from The University of Michigan and his BS in chemistry from The University of Massachusetts, where he was a Shapiro scholar.

Research Interest

 Oncology, Urology, Marine drugs